8:40 am Chair’s Opening Remarks
Bridging the Gap Between Research & Clinical Application of Biomarkers to Meet Patient Need
8:50 am Discussing the Commonalities & Discrepancies Between IBD, Psoriasis & Rheumatoid Arthritis
Synopsis
- Understanding the specific cytokine implications that cause the different autoimmune presentations to better inform drug target developments
- What can be learnt from findings in psoriasis and RA that may inform our molecular understanding of the pathology underlying IBD?
9:20 am Harnessing Non-Invasive Cross-Sectional Imaging for Clinical Prognostication, Risk Stratification & Real-Time Responsiveness
Synopsis
- Utilizing cross-sectional imaging to detect bowel damage and fibrosis with potential for early use in clinical trial enrolment
- Exploring the role of intestinal ultrasound as a non-invasive biomarker of early treatment response and prediction
- Debating transmural healing as a target for disease modification
9:50 am Talk to be given by our Innovation Partner, Karius
10:00 am Morning Break & Poster Session
Synopsis
Present your research to this expert community to gain feedback, benchmark ideas and foster collaboration!
11:00 am Regulatory Perspectives on Qualification of Biomarkers for Drug Development
Synopsis
- Understanding the different ways biomarkers can be utilized in drug development
- Recognizing the different pathways that a biomarker can be qualified for use in drug development
- Facilitating collaboration between researchers, industry, and patient advocacy groups to enable development of biomarkers to address areas of unmet need
11:30 am Roundtable Discussion: Rethinking Patient Evaluation Protocol to Facilitate a Holistic Understanding of IBD & Improve Clinical Trial Design
Synopsis
- Comparing how patients are evaluated clinically, visually and with biopsy to improve integration of the microscopic, macroscopic and clinical aspects of IBD
- Highlighting future steps to ensure a harmonious evaluation of patients with IBD
- Discussing what can be learned from other IMIDs
- Debating how to improve regulatory acceptance of biomarkers of IBD
12:20 pm Talk to be given by our Innovation Partner, Enveda
12:30 pm Lunch Break
Addressing the Future of Collaborative Databases & AI to Improve the Quality of IBD Research
1:30 pm Forging a Path Towards Next-Generation Discoveries Through Building of a Collaborative Research Infrastructure & Ecosystem
Synopsis
- Breaking down data sharing barriers to assemble comprehensive, multimodal longitudinal IBD health journeys to address the unmet need in IBD
- Applying best practices to data standards, models, and analytic methods to facilitate discoveries in IBD
- Leveraging real world evidence to inform/supplement regulatory decisions
2:00 pm Embracing Machine Learning & AI to Increase Reliability of Endpoint Assessment in IBD
Synopsis
- Utilizing AI and machine learning to reduce subjectivity and rater variability
- Using AI for diagnostic image assessments
- Discovering the role of machine learning in IBD therapeutic monitoring to reduce the reliance on invasive diagnostic tools
2:30 pm Developing Novel IBD Therapeutics Using Artificial Intelligence & Machine Learning
Synopsis
- Utilizing artificial intelligence and computational modelling to identify enzyme based novel drug targets
- Harnessing artificial intelligence to identify novel biomarkers of IBD to better inform trial design and patient subgroup
- Leveraging machine learning to improve IBD data analysis
3:00 pm End of Conference Day 2
